Vertex Pharmaceuticals (VRTX) Other Operating Expenses (2009 - 2026)

Vertex Pharmaceuticals' Other Operating Expenses history runs 18 years deep, the most recent figure standing at $393.5 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses fell 48.49% year-over-year to $393.5 million in Q1 2026; TTM through Mar 2026 was $1.8 billion, a 72.4% decrease from a year earlier, with the FY2025 full-year figure at $2.2 billion, down 64.84% from the prior year.
• Other Operating Expenses fell to $393.5 million in Q1 2026 per VRTX's latest filing, from $523.4 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $4.8 billion in Q2 2024 and bottomed at $240.3 million in Q1 2022.
• The 5-year median for Other Operating Expenses is $410.6 million (2025), against an average of $682.0 million.
• Across the five-year window, Other Operating Expenses surged 1052.09% in 2024 and plunged 91.48% in 2025, its largest moves.
• Year by year, Other Operating Expenses stood at $307.7 million in 2022, then increased by 9.03% to $335.5 million in 2023, then soared by 51.92% to $509.7 million in 2024, then increased by 2.69% to $523.4 million in 2025, then slipped by 24.82% to $393.5 million in 2026.
• Per Business Quant, the three latest VRTX Other Operating Expenses figures stand at $393.5 million (Q1 2026), $523.4 million (Q4 2025), and $467.4 million (Q3 2025).